Quinsair

Raptor Pharmaceutical Corp. (NASDAQ: RPTP), a biopharmaceutical company with a focus on developing and commercializing transformative treatments for people affected by rare and debilitating diseases, announced Thursday evening that it has entered into a definitive agreement with Tripex...